1. |
Gröger A, Berg D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies. J Neural Transm, 2012, 119(12): 1523-1528.
|
2. |
Mochizuki H, Yasuda T. Iron accumulation in Parkinson’s disease. J Neural Transm (Vienna), 2012, 119(12): 1511-1514.
|
3. |
Dexter T, Wells R, Agid F,et al. Increased nigral iron content in postmortem Parkinsonian brain. Lancet, 1987, 2(8569): 1219-1220.
|
4. |
Oakley E, Collingwood F, Dobson J,et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology, 2007, 68(21): 1820-1825.
|
5. |
Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord, 2006, 21(9): 1299-1310.
|
6. |
Ward R, Zucca FA, Duyn JH,et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol, 2014, 13(10): 1045-1060.
|
7. |
Antonini A, Leenders L, Meier D,et al. T2 relaxation time in patients with Parkinson’s disease. Neurology, 1993, 43(4): 697-700.
|
8. |
Rutledge JN, Schallert T, Hall S. Magnetic resonance imaging in parkinsonisms. Adv Neurol, 1993, 60: 529-534.
|
9. |
Gorell M, Ordidge J, Brown G,et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology, 1995, 45(6): 1138-1143.
|
10. |
Ryvlin P, Broussolle E, Piollet H,et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson’s disease. Arch Neurol, 1995, 52(6): 583-588.
|
11. |
Atasoy HT, Nuyan O, Tunc T,et al. T2-weighted MRI in Parkinson’s disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India, 2004, 52(3): 332-337.
|
12. |
Kosta P, Argyropoulou MI, Markoula S,et al. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease. J Neurol, 2006, 253(1): 26-32.
|
13. |
Braffman H, Grossman I, Goldberg I,et al. Mr imaging of Parkinson disease with spin-echo and gradient-echo sequences. AJR Am J Roentgenol, 1989, 152(1): 159-165.
|
14. |
Vymazal J, Righini A, Brooks A,et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to Iron content. Radiology, 1999, 211(2): 489-495.
|
15. |
Mondino F, Filippi P, Magliola U,et al. Magnetic resonance relaxometry in Parkinson’s disease. Neurol Sci, 2002, 23(Suppl 2): S87-S88.
|
16. |
Ordidge RJ, Gorell JM, Deniau JC,et al. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med, 1994, 32(3): 335-341.
|
17. |
Baudrexel S, Nürnberger L, Rüb U,et al. Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease. Neuroimage, 2010, 51(2): 512-520.
|
18. |
Graham M, Paley N, Grünewald A,et al. Brain Iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence. Brain, 2000, 123(Pt 12): 2423-2431.
|
19. |
Martin R, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology, 2008, 70(16 Pt 2): 1411-1417.
|
20. |
Peran P, Cherubini A, Assogna F,et al. Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain, 2010, 133(11): 3423-3433.
|
21. |
Wallis I, Paley N, Graham M,et al. MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn Reson Imaging, 2008, 28(5): 1061-1067.
|
22. |
Rossi M, Ruottinen H, Soimakallio Se,et al. Clinical MRI for iron detection in Parkinson’s disease. Clin Imaging, 2013, 37(4): 631-636.
|
23. |
Zhang W, Sun G, Jiang H,et al. Determination of brain iron content in patients with Parkinson’s disease using magnetic susceptibility imaging. Neurosci Bull, 2009, 25(6): 353-360.
|
24. |
Zhang J, Zhang Y, Wang J,et al. Characterizing iron deposition in Parkinson’s disease using susceptibility-weighted imaging: anin vivo MR study. Brain Res, 2010, 1330: 124-130.
|
25. |
Jin L, Wang J, Zhao L,et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease. Brain, 2011, 134(Pt 1): 50-58.
|
26. |
Wang Y, Butros SR, Shuai X,et al. Different iron-deposition patterns of multiple system atrophy with predominant Parkinsonism and idiopathetic parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol, 2012, 33(2): 266-273.
|
27. |
Lotfipour K, Wharton Samuel, Schwarz T,et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. J Magn Reson Imaging, 2012, 35(1): 48-55.
|
28. |
Chen C, Hardy A, Kucharczyk W,et al. Mr of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol, 1993, 14(2): 275-281.
|
29. |
Levy R, Hazrati N, Herrero T,et al. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience, 1997, 76(2): 335-343.
|
30. |
Rossi E, Ruottinen H, Saunamäki T,et al. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson’s disease in the initial stages. Acad Radiol, 2014, 21(1): 64-71.
|
31. |
Lewis M, Du G, Kidacki M,et al. Higher iron in the red nucleus marks Parkinson’s dyskinesia. Neurobiol Aging, 2013, 34(5): 1497-1503.
|
32. |
Bunzeck N, Singh-Curry V, Eckart C,et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson’s disease. Parkinsonism Relat Disord, 2013, 19(12): 1136-1142.
|
33. |
Oberhauser E, Weinstein V, Asenjo A. Iron concentration in basal ganglia and cerebral cortex obtained by overloading rabbits and monkeys with iron dextran. J Neurosurg, 1970, 32(6): 677-679.
|
34. |
Ulla M, Bonny JM, Ouchchane L,et al. Is R2* a new MRI biomarker for the progression of Parkinson’s disease? A longitudinal follow-up. PLoS One, 2013, 8(3): e57904.
|
35. |
Boelmans K, Holst B, Hackius M,et al. Brain iron deposition fingerprints in Parkinson’s disease and progressive supranuclear palsy. Mov Disord, 2012, 27(3): 421-427.
|
36. |
Zhu Z, Zhong D, Wang W,et al. Quantitative Mr phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology, 2009, 253(2): 497-504.
|